GENinCode PLC (LSE:GENI) has spent 2026 rebuilding after a bruising year. The cardiovascular genetics company raised £4.7m at just 1p a share in February, warned in its Annual Report of a material uncertainty over going concern, and has seen its shares fall from a 52-week high of 4.85p last September to around 0.95p in early September 2026, according to lse.co.uk, valuing the Business at roughly £7m.
Yet the newsflow has not been uniformly bleak. On 28 August 2026 the company published real-world results from an 18-month pilot of its CARDIO inCode-Score polygenic risk test in Catalonia, presented at the European Society of Cardiology Congress in Munich. With a fresh US Food and Drug Administration (FDA) submission targeted for the current quarter and a Thermo Fisher Scientific distribution deal in place, the question is whether the science can translate into Revenue before the cash runs short.
Catalonia pilot: genetic testing changed risk assessment for 42.6% of patients
The 28 August announcement covered a pilot run by the Institut Català de la Salut (ICS) across 14 primary care centres. Some 584 patients aged 45 to 65, all classified as moderate cardiovascular risk by conventional tools, were given the CARDIO inCode-Score test and followed at six and twelve months.
Adding the polygenic risk score altered the overall risk assessment in 42.6% of patients, the company said, with 26.5% changing risk category outright. Over a mean follow-up of 8.5 months, average cardiovascular risk fell from 7.30% to 6.04%, LDL cholesterol dropped from 136.74 mg/dL to 123.17 mg/dL, and sustained smoking abstinence rose from 43.7% to 62.8%, all with p-values below 0.0001.
Dr Elisabet Descals, Primary Care Director at ICS, said the results "provide further real-world clinical evidence for the inclusion of polygenic risk scores in conjunction with clinical risk for improved risk assessment of CAD in primary care moderate-risk patients."
What GENinCode does
GENinCode develops genetic tests for predicting and preventing cardiovascular disease. Its flagship CARDIO inCode-Score is a polygenic risk score for coronary artery disease that combines a patient's genetic profile with conventional clinical risk factors, supported by LIPID inCode for familial hypercholesterolaemia, THROMBO inCode for thrombotic risk, SUDD inCode for sudden cardiac death, and the ROCA test for ovarian cancer risk.
The group earns revenue by selling tests through its own laboratories or via partners. Spain remains by far the largest market, generating £2.1m of the £3.1m FY25 total, followed by the UK (£538k), Italy (£187k), the US (£155k) and Germany (£87k). In the UK it runs an NHS LIPID inCode service in the North East and in October 2025 won its first NHS ROCA contract with University College London Hospitals.
The US is the strategic prize. CARDIO inCode-Score sits on the 2025 Medicare Clinical Laboratory Fee Schedule at about $500 per test, and in March 2026 polygenic risk scores were added to US cardiology guidelines as a "risk enhancer". In December 2025 Thermo Fisher agreed to manufacture, sell and distribute the test on its QuantStudio 5 Dx platform across the US and EMEA; no financial terms were disclosed.
FY25 results: revenue up 14%, losses wider, cash down to £0.8m
Final results for the year to 31 December 2025, published on 8 June 2026, showed revenue of £3.1m, up 14% from £2.7m, with gross Margin improving to 59% from 53%, although sales fell short of the £3.3m guided at the interim stage.
The operating loss widened to £5.9m from £5.1m as commercial teams were built out, and the adjusted EBITDA loss grew to £4.9m from £4.4m. Basic loss per share narrowed to 2.08p from 2.53p on a larger share count. Net cash used in Operating Activities fell to £4.1m from £5.2m, but year-end cash was only £0.8m, down from £1.1m, with borrowings limited to £146k of Lease liabilities.
The February 2026 placing, subscription and retail offer raised £4.7m through 466.2m new shares at 1p, a 47.4% discount to the previous close of 1.9p, lifting shares in issue to 753.0m. The placing announcement warned that failure to secure the funds "could lead to insufficient Capital to continue trading", and the annual report's going-concern note later described "a material uncertainty which may cast significant doubt", although the directors pointed to "a proven track record in raising funds".
Revenue in the first four months of 2026 was "broadly in line" with the same period of 2025 despite lower NHS and Catalonia pilot income, with more than 70 US institutions onboarded. Chief executive Matthew Walls said the company is "well positioned to accelerate growth".
What could drive the stock next?
The key milestone is regulatory. After the FDA identified deficiencies in the original De Novo submission in April 2025, chiefly around clinical validation, GENinCode agreed a programme with the agency that draws on ongoing Kaiser Permanente studies for multi-ethnic data. It expects to lodge a new De Novo application in the third quarter of 2026, targeting approval by year-end, and has said US test volumes should "materially increase" once approval and expanded insurance coverage arrive.
Interim results for the six months to 30 June 2026 are the next scheduled event; last year's came on 30 September. Investors will look for evidence that US orders and the Thermo Fisher collaboration are showing up in revenue, and that 2026 targets of higher sales, better margins and lower EBITDA losses remain intact.
Risks investors should watch
Funding is the central risk. With £0.8m of cash at the end of 2025, a £4.7m raise in February and a £4.1m operating cash outflow last year, the accounts flag material uncertainty over going concern. Unless losses narrow sharply, another Equity raise is plausible; the last one was priced at a 47% discount and lifted the share count from 286.9m to 753.0m.
Regulatory execution is the second risk. The FDA has already found deficiencies in one submission, and the company cautioned in 2025 that "there can be no certainty" that additional information will suffice. Further delay would push out the US revenue inflection on which the Investment case rests.
Revenue concentration also matters: Spain provides about two-thirds of sales, NHS budgets are under pressure, Catalonia pilot income has already declined, and US revenue was just £155k in 2025. The shares are also illiquid, with a bid-offer spread above 10% in early September, according to lse.co.uk.
Outlook
GENinCode enters the autumn with two live catalysts: an FDA resubmission and interim results that should reveal whether US commercial momentum is real. The Catalonia pilot has added credible evidence to the case for polygenic risk scoring, and the Thermo Fisher Partnership offers distribution reach a 45-person company could not build alone.
Against that, the Balance Sheet remains thin, losses still run well ahead of revenue, and the going-concern language in the FY25 accounts is a reminder that the company's timeline is not entirely its own. Whether GENI proves a sleeper or a serial diluter will depend on the FDA's verdict and how quickly reimbursed US testing converts into cash.



_11_18_2026_14_37_47_487896.jpg)


Please wait processing your request...